Amprius Stock Surges on Reported 2025 Sales Triple, But Scale-Up Execution Remains Unproven

What happened

Amprius Technologies' stock surged today following a news article highlighting that the company more than tripled its sales in 2025. This likely stems from the release of Q4 and full-year 2025 results on March 5, 2026, a key milestone identified in the DeepValue report for assessing backlog and margin trends. The report had noted revenue scaling to a $21.4 million quarterly run-rate in Q3'25 with a 15% gross margin, but emphasized that the business remains partner-dependent and loss-making. Critical risks include converting the $53.3 million backlog into replenished orders beyond a single large customer and sustaining positive gross margins amid volatile partner pricing. Investors should view this surge with skepticism, as the underlying thesis requires proof of durable execution over the next 6-9 months, not just top-line growth.

Implication

Short-term, the stock reaction reflects market enthusiasm for revenue acceleration, yet financials still show negative earnings and free cash flow, underscoring valuation risks. Medium-term, the company must demonstrate that sales growth translates into repeat, diversified orders to reduce the 35% single-customer concentration and validate the reorder cadence thesis. Gross margin sustainability is precarious due to partner manufacturing with no preset commercial terms, requiring vigilant monitoring of upcoming quarterly reports. The NDAA qualification target by mid-2026 remains a critical gating factor for defense scale, and any delay could undermine the bull case. Consequently, while the news is positive, it does not alter the need for cautious positioning until evidence of operational control emerges.

Thesis delta

The reported sales triple aligns with the DeepValue base scenario of revenue near a $70M-$90M annual run-rate, partially validating demand pull. However, the investment thesis remains unchanged, as it hinges on observable proof of backlog replenishment and gross margin staying above 10% for two quarters, which are not addressed by this headline alone. Investors should still wait for detailed results to assess these factors before considering entry.